Janet M. Yoon MD
Medical Director, Pediatric Musculoskeletal Tumors Program at city of Hope
Join to View Full Profile
1500 Duarte RdDuarte, CA 91010
Phone+1 626-256-4673
Dr. Yoon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am a board-certified pediatric hematologist/oncologist specializing in bone and soft tissue sarcomas. I am a clinical professor within the department of pediatrics and am the medical director of the Pediatric Musculoskeletal Tumors Program at City of Hope. I lead our pediatric clinical research program by serving as the Principal Investigator of the Children's Oncology Group. I also work closely with our adult sarcoma colleagues to bring innovative clinical trials to City of Hope, specifically for the adolescent and young adult population.
Education & Training
Children's Hospital Los AngelesFellowship, Pediatric Hematology/Oncology, 2003 - 2007
Medical University of South CarolinaResidency, Pediatrics, 2000 - 2003
The University of Toledo College of MedicineClass of 2000
Certifications & Licensure
CA State Medical License 2002 - 2026
SC State Medical License 2002 - 2003
American Board of Pediatrics Pediatric Hematology-Oncology
Publications & Presentations
PubMed
- 1 citationsBioinformatic Analysis of Recurrent Genomic Alterations and Corresponding Pathway Alterations in Ewing Sarcoma.Adam Rock, An Uche, Janet Yoon, Mark Agulnik, Warren Chow
Journal of Personalized Medicine. 2023-10-15 - 1 citationsCardiovascular toxicities with pediatric tyrosine kinase inhibitor therapy: An analysis of adverse events reported to the Food and Drug Administration.Hari K Narayan, Karyn Sheline, Victor Wong, Dennis Kuo, Sun Choo
Pediatric Blood & Cancer. 2023-02-01 - 61 citationsEntrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).Ami V Desai, Giles W Robinson, Karen Gauvain, Ellen M Basu, Margaret E Macy
Neuro-Oncology. 2022-10-03
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
